As one of the few tests with these indications, the Helix® COVID-19 Test provides organizations with significantly more flexibility in how they operate testing sites to support broad back-to-work and school screening
SAN MATEO, Calif., Oct. 26, 2020… […]
SAN DIEGO, Oct. 22, 2020 /PRNewswire/ — Halozyme Therapeutics, Inc. (NASDAQ: HALO) will webcast its Quarterly Update Conference Call for the third quarter 2020 on Monday, November 2 at 4:30 p.m. ET / 1:30 p.m. PT. Dr. Helen Torley, president and c… […]
Conference Call Scheduled for Wednesday, October 28 at 4:30 p.m. Eastern Time
SAN DIEGO, Oct. 21, 2020 /PRNewswire/ — Viking Therapeutics, Inc. (“Viking”) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel… […]
Partnership Leverages TScan’s Proprietary High-throughput TCR/Target Discovery Platform and Poseida’s Proprietary Allogeneic T Cell Approach to Advance Potential TCR-T Treatments
SAN DIEGO and WALTHAM, Mass., Oct. 21, 2020 /PRNewswire/ — Poseida The… […]
– Adaptive Clinical Trial Platform in Glioblastoma Multiforme — Expected to serve as basis for VAL-083’s new drug application (NDA) submission and registration- Expansion of clinical site involvement with 31 U.S. sites actively enrolling patients; i… […]
Diagnostic industry veteran plans immediate start
SAN DIEGO, Oct. 21, 2020 /PRNewswire/ — Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider of molecular diagnostic tests and services, announces the appointment of Samuel D. Riccitelli to it… […]
– Randomized, placebo controlled, clinical trial is being conducted at University of Kansas Medical Center, Kansas City, Kansas- Enrolling highly symptomatic participants within 28 days of injury- First in class investigational drug to potentially t… […]
— Trial on track to meet prespecified criteria for success on its primary endpoint, with 31% (8/26) disease control rate in evaluable patients in cohorts A and B. Patients eligible for the trial have two consecutive rises in PSA levels indicating init… […]
SAN DIEGO, Oct. 19, 2020 /PRNewswire/ — NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced the Company will r… […]
– Data continue to support the unique clinical attributes for Neurelis’ lead product, VALTOCO® (diazepam nasal spray), the first and only nasal spray treatment for seizure cluster rescue in pediatric patients 6 years of age and older, adolescents, and … […]
Copyright © 2020 | MH Magazine WordPress Theme by MH Themes
